ArticleTherapeutic advances in musculoskeletal disease2011
Efficacy and safety of febuxostat in patients with hyperuricemia and gout.
Article in Therapeutic advances in musculoskeletal disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis.Medicine · 2019Pooled it
- Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects.Drug design, development and therapy · 2015Trial
- Trial
- Sex-stratified disproportionality signals of adverse events with allopurinol and febuxostat: a retrospective pharmacovigilance analysis of FAERS and EudraVigilance.Clinical rheumatology · 2026Article
- Serum Uric Acid-Reducing Effect and Intestinal Mucosal Barrier-Repairing Function ofMicroorganisms · 2026Article
- Thiazole: A Versatile Standalone Moiety Contributing to the Development of Various Drugs and Biologically Active Agents.Molecules (Basel, Switzerland) · 2022Review
- Xanthine Oxidase Inhibitor, Febuxostat Is Effective against 5-Fluorouracil-Induced Parotid Salivary Gland Injury in Rats Via Inhibition of Oxidative Stress, Inflammation and Targeting TRPC1/CHOP Signalling Pathway.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2020Article
- Synthesis and characterization of CAPE derivatives as xanthine oxidase inhibitors with radical scavenging properties.Bioorganic chemistry · 2019Article
- The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.Clinical and experimental nephrology · 2018Observational
- Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial.EXCLI journal · 2018Article
- Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.Journal of managed care & specialty pharmacy · 2016Observational
- Hydroxylated chalcones with dual properties: Xanthine oxidase inhibitors and radical scavengers.Bioorganic & medicinal chemistry · 2016Article
- Therapeutic approaches to chronic hyperuricemia and gout.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2014Review
- Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome.Oncology letters · 2014Article
- Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice.Scientific reports · 2014Article
- The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past decade has witnessed an exponential increase of novel therapeutic modalities for a variety of rheumatic disorders, including gout. During the past few years two novel therapeutic agents have been approved by the US Food and Drug Administration for the treatment of hyperuricemia in patients with gout, one of them being febuxostat, a nonpurine selective inhibitor of xanthine oxidase. Review of its pharmacokinetics and pharmacodynamics, efficacy and safety profile, and use in gout patients with comorbid conditions reveals that age and gender have no clinically significant effect and dose adjustments based on age or gender are not required. In addition, febuxostat can be used in patients with mild-to-moderate renal or hepatic involvement. Its overall efficacy and safety profile is comparable and, in certain subsets such as gout patients with mild and moderate renal insufficiency, is superior to allopurinol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.